Oculis Holding Ag (OCS)
NASDAQ:OCS
Want to see OCS full AI Analyst Report?
OCS Stock Chart & Stats
$27.46
$0.20(1.10%)
At close: 4:00 PM EST
$27.46
$0.20(1.10%)
Day’s Range― - ―
52-Week Range$16.00 - $34.48
Previous CloseN/A
Volume95.89K
Average Volume (3M)472.52K
Market Cap
$1.70B
Enterprise Value$1.27B
Total Cash (Recent Filing)$221.37M
Total Debt (Recent Filing)$2.24M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Aug 06, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.73
Shares Outstanding57,169,476
10 Day Avg. Volume394,098
30 Day Avg. Volume472,520
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue2.51K
Enterprise Value/Gross Profit-86.96
Enterprise Value/Ebitda-14.94
Forecast
1Y Price Target
$52.75Price Target Upside92.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.75
Revenue Forecast (FY)$5.27M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutsAnalyst highlights that pivotal Phase 3 readouts for OCS-01 topical eye drops could enable a New Drug Application filing if results are positive, potentially introducing a noninvasive treatment for diabetic macular edema.
Regulatory PathwayAnalyst notes that Breakthrough Therapy designation for privosegtor may accelerate development and attract intensive FDA guidance, supporting a faster regulatory review path for optic neuritis.
Targeted Therapy DevelopmentAnalyst emphasizes that a genotype-targeted registrational trial for licaminlimab represents a precision medicine strategy that could deliver differentiated benefit for a specific dry eye patient subgroup.
Bears Say
Financial PerformanceReported sizable annual net loss signals significant cash burn, raising concerns about the company's ability to sustain operations without additional funding.
Financing And Dilution RiskHigh cash burn relative to available cash increases the likelihood of a capital raise, which could dilute existing shareholders and weigh on the stock.
Liquidity Pressure On DevelopmentSustained cash outflows may force reprioritization of clinical programs or slow trial enrollment if additional capital is not secured, creating execution risk.
Oculis Holding News
OCS FAQ
What was Oculis Holding Ag’s price range in the past 12 months?
Oculis Holding Ag lowest stock price was $16.00 and its highest was $34.48 in the past 12 months.
What is Oculis Holding Ag’s market cap?
Oculis Holding Ag’s market cap is $1.70B.
When is Oculis Holding Ag’s upcoming earnings report date?
Oculis Holding Ag’s upcoming earnings report date is Aug 06, 2026 which is in 68 days.
How were Oculis Holding Ag’s earnings last quarter?
Oculis Holding Ag released its earnings results on May 11, 2026. The company reported -$0.623 earnings per share for the quarter, missing the consensus estimate of -$0.509 by -$0.114.
Is Oculis Holding Ag overvalued?
According to Wall Street analysts Oculis Holding Ag’s price is currently Undervalued.
Does Oculis Holding Ag pay dividends?
Oculis Holding Ag does not currently pay dividends.
What is Oculis Holding Ag’s EPS estimate?
Oculis Holding Ag’s EPS estimate is -0.51.
How many shares outstanding does Oculis Holding Ag have?
Oculis Holding Ag has 57,169,476 shares outstanding.
What happened to Oculis Holding Ag’s price movement after its last earnings report?
Oculis Holding Ag reported an EPS of -$0.623 in its last earnings report, missing expectations of -$0.509. Following the earnings report the stock price went down -6.861%.
Which hedge fund is a major shareholder of Oculis Holding Ag?
Currently, no hedge funds are holding shares in OCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oculis Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.75 (92.10% Upside)
$52.75 (92.10% Upside)
Blogger Sentiment
Bullish
OCS Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.43%
12-Months-Change
Fundamentals
Return on Equity
-57.09%
Trailing 12-Months
Asset Growth
31.58%
Trailing 12-Months
Company Description
Oculis Holding Ag
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
OCS Stock 12 Month Forecast
Average Price Target
$52.75
▲(92.10% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Spyre Therapeutics
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Upstream Bio, Inc.
―
Ownership Overview
―
Insiders
1.58% Mutual Funds
26.35% Other Institutional Investors
71.76% Public Companies and
Individual Investors